HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis.

AuthorsL Smaldone, P Plezia, D Alberts, M Aapro, G Sartiano, M Dorn, M Brady, C Comerski, S E Schwartz, C Fairchild
JournalCancer treatment reviews (Cancer Treat Rev) Vol. 17 Issue 2-3 Pg. 319-27 (Sep 1990) ISSN: 0305-7372 [Print] Netherlands
PMID2272047 (Publication Type: Journal Article, Review)
Chemical References
  • Antiemetics
  • Antineoplastic Agents
  • Dopamine Antagonists
  • Serotonin Antagonists
  • batanopride
  • Metoclopramide
  • Cisplatin
Topics
  • Animals
  • Antiemetics (pharmacokinetics, therapeutic use)
  • Antineoplastic Agents (adverse effects)
  • Cisplatin (adverse effects)
  • Dogs
  • Dopamine Antagonists
  • Female
  • Ferrets
  • Hemodynamics (drug effects)
  • Humans
  • Male
  • Metoclopramide (analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)
  • Mice
  • Middle Aged
  • Neoplasms (drug therapy)
  • Rats
  • Serotonin Antagonists (pharmacokinetics, therapeutic use)
  • Vomiting (chemically induced, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: